You are on Trendlyne United States. Click here to go to India website or make United States as your default

2.60 -0.04 (-1.52%)

64.14% Fall from 52W High

320.1K XNAS Volume

XNAS 28 Mar, 2025 5:30 PM (EDT)

Not Eligible
-
Expensive Valuation
13.5 / 100
Technically Bearish
33.6 / 100

Acelyrin Inc Live Price Chart

Switch to TradingView
Created with Highcharts 9.0.1Chart context menu22. Apr20. May17. Jun15. Jul12. Aug9. Sep7. Oct4. Nov2. Dec30. Dec27. Jan24. Feb24. MarJul '23Oct '23Jan '24Apr '24Jul '24Oct '24Jan '2524680020MZoom1D1W1M3M1Y5YAllMar 28, 2024Mar 28, 2025trendlyne.com

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Acelyrin Inc Stock Analysis

Acelyrin Inc stock analysis with key metrics, changes, and trends.

Acelyrin Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Net Profit$248.23 M34.96%positive

Annual Net Profit rose 34.96% in the last year to $248.23 M. Its sector's average net profit growth for the last fiscal year was -32.42%.

Price to Earning Ratio-1.05-negative

Price to Earning Ratio is -1.05, which is negative.

Stock Price$2.60-61.48%negative

Stock Price fell 61.48% and underperformed its sector by 67.15% in the past year.

Quarterly Net profit$79.03 M16.99%positive

Quarterly Net profit rose 16.99% YoY to $79.03 M. Its sector's average net profit growth YoY for the quarter was -47.39%.

Mutual Fund Holding35.97 %-1.04%negative

Mutual Fund Holding decreased by 1.04% in the last quarter to 35.97.

Institutional Holding80.35 %0%neutral

Institutional Holding remained the same in the last quarter at 80.35%.

VIEW LESS


Loading data..

Acelyrin Inc - Company Profile

What does Acelyrin Inc do?

Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.

Acelyrin Inc Management structure

All Gross Remunerations are in USD
Mr. Gil M. Labrucherie
Chief Business Officer, Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Ms. Mina Kim
Director; Chief Executive Officer; Principal Financial Officer and Principal Accounting officer
-
2024
Gross Remuneration
Year
Dr. Shao-Lee Lin, M.D.,PhD
Founder, Chief Executive Officer and Director
-
2024
Gross Remuneration
Year
Mr. Ron Oyston
Chief People Officer
-
2024
Gross Remuneration
Year
Mr. Shephard Mpofu, M.D.
Chief Medical Officer
-
2024
Gross Remuneration
Year
Ms. Sanam Pangali
Chief Legal Officer and Head of People
-
2024
Gross Remuneration
Year

Acelyrin Inc Board of directors

All Gross Remunerations are in USD
Ms. Mina Kim
Director; Chief Executive Officer; Principal Finan
-
2024
Gross Remuneration
Year
Dr. Shao-Lee Lin, M.D.,PhD
Founder, Chief Executive Officer and Director
-
2024
Gross Remuneration
Year
Dr. Beth C. Seidenberg,M.D.
Independent Director
-
2024
Gross Remuneration
Year
Mr. Bruce C. Cozadd
Chairman of the Board
-
2024
Gross Remuneration
Year
Mr. Patrick C. Machado, J.D.
Independent Director
-
2024
Gross Remuneration
Year
Dr. Alan B. Colowick, M.D.,M.P.H.
Independent Director
-
2024
Gross Remuneration
Year

Acelyrin Inc FAQ

How is Acelyrin Inc today?
Acelyrin Inc today is trading in the red, and is down by -1.52% at 2.60.
Acelyrin Inc is currently trading down -1.52% on an intraday basis. In the past week the stock fell -5.45%. stock has been down -20.00% in the past quarter and fell -61.48% in the past year. You can view this in the overview section.